Ends in "ib" or "ab"
This “ab” selectively targets cytotoxic T-lymphocyte-associated protein 4.
Tremelimumab
This trials namesake flows through 10 countries, more than any other in the world and is expected to read out early next year.
DANUBE
HBV and HCV are the most common risk factors for this disease.
Hepatocellular carcinoma
DANUBE
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer
If you have trouble fixing things, this “ab” may be able to help.
Olaparib
This trial looks at TACE plus durvalumab monotherapy or in combination with Bevacizumab in and is named after this South American Mountain range.
EMERALD-1
BRCA mutations are commonly associated with this form of XX cancer.
Ovarian cancer
HIMALAYA
First randomized, open-label, multicenter, Phase 3 study to assess the efficacy and safety of D plus T combination therapy and D monotherapy versus sorafenib in the first-line treatment of patients with unresectable, histologically confirmed HCC.
One of four types of human blood
AB
This study looks at a disease associated of Everest proportions with Hepatitis B and C, combining durvalumab and tremelimumab in first line treatment.
HIMALAYA
This form of cancer is highly associated with smokers and exposure to chemical irritants.
Bladder cancer
EMERALD-1
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma
In ovarian cancer, this “ab” was recently shown to significantly delay disease progression in the 1st line.
Olaparib
This slow-moving river or wetland aptly describes how quickly this trial has been recruiting in Canada.
BAYOU
Being a male is the most common risk factor for this cancer.
Prostate cancer
POTOMAC
A randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer.
This “ab” not only blocks its intended receptor, it also blocks CD-80.
Durvalumab
If you received the vaccine in this clinical trial, you would test positive on a TB test requiring a chest X-ray to rule out tuberculosis.
POTOMAC
Diabetes is an early sign of this disease.
Pancreatic cancer
PROpel
A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel